Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABSW), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
SAB Biotherapeutics reports news as a clinical-stage biopharmaceutical company developing human immunoglobulin G therapies for immune and autoimmune disorders. Its recurring updates center on SAB-142, a fully human anti-thymocyte immunoglobulin (hATG) candidate for type 1 diabetes and other autoimmune diseases, supported by the company’s Tc-Bovine™ platform for producing targeted human IgG without human donors or convalescent plasma.
Company announcements also cover clinical data releases, development funding, public offerings of common stock and pre-funded warrants, manufacturing arrangements, board composition, annual financial results, and investor-conference participation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.